Novo Nordisk CEO Mike Doustdar said during the company’s August 5 earnings call that innovation will determine whether the Danish drugmaker can sustain long-term growth. His comments followed the Phase 3 ZEUS trial failure for ziltivekimab and other pipeline setbacks.
